Abstract:Obesity is a lipid metabolism disorder caused by genetic, medicinal, nutritional, and other environmental factors. It is characterized by a complex condition of excess lipid accumulation in adipocytes. Adipogenesis is a differentiation process that converts preadipocytes into mature adipocytes and contributes to excessive fat deposition. Saikosaponin A (SSA) and saikosaponin D (SSD) are triterpenoid saponins separated from the root of the Bupleurum chinensis, which has long been used to treat inflammation, fever, and liver diseases. However, the effects of these constituents on lipid accumulation and obesity are poorly understood. We investigated the anti-obesity effects of SSA and SSD in mouse 3T3-L1 adipocytes. The MTT assay was performed to measure cell viability, and Oil Red O staining was conducted to determine lipid accumulation. Various adipogenic transcription factors were evaluated at the protein and mRNA levels by Western blot assay and quantitative reverse transcription polymerase chain reaction (qRT-PCR). Here, we showed that SSA and SSD significantly inhibited lipid accumulation without affecting cell viability within the range of the tested concentrations (0.938–15 μM). SSA and SSD also dose-dependently suppressed the expression of peroxisome proliferator-activated receptor gamma (PPARγ), CCAAT/enhancer binding protein alpha (C/EBPα), sterol regulatory element binding protein-1c (SREBP-1c), and adiponectin. Furthermore, the decrease of these transcriptional factors resulted in the repressed expression of several lipogenic genes including fatty acid binding protein (FABP4), fatty acid synthase (FAS), and lipoprotein lipase (LPL). In addition, SSA and SSD enhanced the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and its substrate, acetyl-CoA carboxylase (ACC), and inhibited the phosphorylation of extracellular-regulated kinase 1/2 (ERK1/2) and p38, but not c-Jun-N-terminal kinase (JNK). These results suggest that SSA and SSD inhibit adipogenesis through the AMPK or mitogen-activated protein kinase (MAPK) pathways in the early stages of adipocyte differentiation. This is the first study on the anti-adipogenic effects of SSA and SSD, and further research in animals and humans is necessary to confirm the potential of saikosaponins as therapeutic agents for obesity.

Inhibition of Lysosomal Cathepsin A and Neuraminidase 1 Interaction by Anti-obesity Cyclic Peptide

Ganoderic Acid A improves high fat diet-induced obesity, lipid accumulation and insulin sensitivity through regulating SREBP pathway

Cover Feature: Inhibition of Lysosomal Cathepsin A and Neuraminidase 1 Interaction by Anti‐Obesity Cyclic Peptide (Chem. Eur. J. 56/2024)

Obesity-related metabolic disorders mitigated by peptides designed to modulate adiponectin assembly.

Saikosaponin A and D Inhibit Adipogenesis via the AMPK and MAPK Signaling Pathways in 3T3-L1 Adipocytes

Pharmacological Approaches to Attenuate Inflammation and Obesity with Natural Products Formulations by Regulating the Associated Promoting Molecular Signaling Pathways

The Full Capacity of Aicar to Reduce Obesity-Induced Inflammation and Insulin Resistance Requires Myeloid Sirt1

Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study

Prevention of Obesity in Mice by Antisense Oligonucleotide Inhibitors of Stearoyl-Coa Desaturase-1.

A Novel Peptide Suppresses Adipogenic Differentiation Through Activation of the AMPK Pathway.

Identification and Molecular Binding Mechanism of Novel Pancreatic Lipase and Cholesterol Esterase Inhibitory Peptides from Heat-Treated Adzuki Bean Protein Hydrolysates.

Annexin A1 binds PDZ and LIM domain 7 to inhibit adipogenesis and prevent obesity

Synthesis and Characterization of Short α and β-Mixed Peptides with Excellent Anti-Lipase Activities

A Multitarget Angiogenesis Inhibitor, CTT Peptide-Endostatin Mimic-Kringle 5, Prevents Diet-Induced Obesity

Peripheral Cathepsin L Inhibition Induces Fat Loss in C. Elegans and Mice Through Promoting Central Serotonin Synthesis.

Dietary pyruvate targets cytosolic phospholipase A2 to mitigate inflammation and obesity in mice

Pyrazolone compounds could inhibit CES1 and ameliorates fat accumulation during adipocyte differentiation

Piceatannol antagonizes lipolysis by promoting autophagy-lysosome-dependent degradation of lipolytic protein clusters in adipocytes

A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice

Separation And Lipid Inhibition Effects Of A Novel Decapeptide From Chlorella Pyenoidose

A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys